非奈利酮能治好糖尿病肾病吗？

Fenelidone cannot cure diabetic nephropathy, it can only relieve symptoms and delay disease progression.

The latest research results suggest that blocking aldosterone receptors while giving standard treatments can reduce proteinuria in patients with diabetic nephropathy and chronic kidney disease, and has a potential protective effect on organ damage. The third-generation aldosterone receptor antagonist fenelidone has good curative effect on heart failure, has an important protective effect on the kidneys, and has few sex hormone-related adverse reactions.

New drug for treating diabetic nephropathy——

In recent years, the incidence of chronic heart failure caused by diabetic nephropathy has increased rapidly, and effective drugs are still lacking. Fenelidone is a new generation of oral nonsteroidal mineralocorticoid receptor antagonists that blocks the harmful effects of overactivation of mineralocorticoid receptors caused by aldosterone and can be used in patients with severe renal impairment. Several clinical trial studies have shown that fenelidone has good safety and efficacy.

Diabetic kidney disease (DKD) is a complication of systemic microvascular disease in diabetes. DKD is often complicated by microvascular diseases of other organs or systems, such as diabetic retinopathy, peripheral neuropathy, etc. Diabetes is also a major cause of chronic kidney disease and cardiovascular disease.

In the past decade or so, research on mineralocorticoid receptor antagonists (MRA) has achieved great results. This type of drug can block cell damage caused by excessive activation of the mineralocorticoid receptor (MR) and is beneficial to the recovery of heart and kidney function. However, the accompanying hyperkalemia, inflammatory diseases, fibrosis, etc., limit its widespread clinical use. The new generation of non-steroidal selective MRA fenelinone developed by Bayer Healthcare Pharmaceuticals in Germany has shown to significantly reduce the composite risk of non-fatal events such as cardiovascular death or myocardial infarction, stroke or hospitalization for heart failure for the first time, as well as eliminate important pathogenic factors of renal and cardiovascular damage, and can prevent various injuries caused by excessive activation of MR and the resulting inflammatory disease and fibrosis process. It has been shown to be effective and safe in reducing cardiovascular disease morbidity and mortality in patients with type 2 diabetes and chronic kidney disease.

Can fenelidone cure diabetic nephropathy?

Fenelidone cannot cure diabetic nephropathy, but Fenelidone is a new nonsteroidal mineralocorticoid receptor antagonist (MRA) that can bring dual heart and kidney benefits to DKD patients.

Excessive activation of the mineralocorticoid receptor (MR) can lead to the progression of chronic kidney disease (CKD). The new MR antagonist, finerenone, has a nonsteroidal structure and can bind to MR through a unique mechanism to inhibit the recruitment of transcriptional cofactors involved in gene expression, thereby inhibiting the progression of diabetic nephropathy (DN). Clinical trials have shown that fenelidone brings both cardiac and renal benefits to patients with type 2 diabetic nephropathy and has good safety. It is expected to become a "troika" in the management of diabetic nephropathy together with renin-angiotensin system blockers and sodium-glucose co-transporter 2 inhibitors.

Fennelidone reduces new-onset atrial fibrillation in diabetic nephropathy

Type 2 diabetes is an independent risk factor for the occurrence of atrial fibrillation. The risk of atrial fibrillation is doubled when it progresses to diabetic nephropathy (DN), and the prognosis of concurrent atrial fibrillation becomes worse. Fenelidone is a nonsteroidal mineralocorticoid receptor antagonist that has protective effects on the heart and kidneys in patients with heart failure and chronic kidney disease. Studies have shown that fenelidone reduces the incidence of atrial fibrillation while treating diabetes-related chronic kidney disease, bringing new hope to patients with DN in the prevention and treatment of atrial fibrillation.

Summary

Diabetic nephropathy is a complication caused by long-term hyperglycemia in diabetic patients, mainly manifesting as renal function damage. Although fenelidone may have a certain improvement effect on diabetic nephropathy, it does not cure diabetic nephropathy and can only be used as one of the auxiliary treatments.

The key to treating diabetic kidney disease is to control blood sugar levels and blood pressure to slow further damage to kidney function. In addition to the standardized use of drugs (such as antidiabetic drugs, antihypertensive drugs, etc.), diet control, moderate exercise and regular monitoring are also required. When treating diabetic nephropathy, it is important to have comprehensive treatment, including multidisciplinary team management, to minimize the development of complications. It is recommended that patients develop the most suitable treatment plan under the guidance of a doctor.

Recommended related articles: